Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Colomb. med ; 54(4): e2005766, Oct.-Dec. 2023. tab, graf
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1574799

RESUMEN

Abstract Background: Intermittent theta-burst stimulation and repetitive peripheral magnetic stimulation can improve motor function in poststroke patients, but the therapeutic effect of this combination remains unclear. Objective: To determine the effects of central intermittent theta-burst stimulation and repetitive peripheral magnetic stimulation on upper limb function. Methods: Fifty-six subacute stroke patients were randomly assigned to three groups: the CMS (n = 18), peripheral magnetic stimulation (PMS) (n = 19) and CPS (n = 19) groups. The CMS group received intermittent theta-burst stimulation and peripheral false stimulation, while the PMS group received repetitive peripheral magnetic stimulation and central false stimulation once a day for five days a week over four weeks. The CPS group received intermittent theta-burst stimulation and repetitive peripheral magnetic stimulation simultaneously once daily for four weeks. The Fugl-Meyer Assessment, Action Research Arm Test, Modified Barthel Index and Modified Ashworth Scale evaluated outcomes before and after four weeks of treatment. Results: The motor function scores of all groups were significantly increased after treatment compared with before treatment, while the Modified Ashworth Scale score showed no significant change. There was a significant difference in the motor function score of the CPS group compared with that of the CMS and PMS groups, but there was no significant improvement in the Modified Ashworth Scale score. Conclusion: Combining the two treatment methods can improve patients' motor function and daily living abilities but cannot improve muscle tone.


Resumen Antecedentes: La estimulación intermitente de theta-burst y la estimulación magnética periférica repetitiva pueden mejorar la función motora en pacientes postictus, pero el efecto terapéutico de esta combinación sigue sin estar claro. Objetivo: Determinar el efecto de la estimulacion central intermitente theta-burst y la estimulación magnética repetitiva periférica en la función del miembro superior. Métodos: Se asignaron aleatoriamente a tres grupos 56 pacientes con ictus subagudo: CMS (n = 18), estimulación magnética periferica (PMS) (n = 19) y CPS(Cm1) (n = 19). El grupo CMS recibió estimulación intermitente de theta-burst y falsa estimulación periférica, el grupo PMS recibió estimulación magnética periférica repetitiva y falsa estimulación central una vez al día durante cinco días a la semana a lo largo de cuatro semanas. El grupo SPC recibió estimulación intermitente theta-burst y estimulación magnética periférica repetitiva simultáneamente una vez al día durante cuatro semanas. Se utilizaron la Fugl-Meyer Assessment, Action Research Arm Test, Modified Barthel Index and Modified Ashworth Scale para evaluar losresultados antes y después de cuatro semanas de tratamiento. Resultados: Las puntuaciones de la función motora de todos los grupos aumentaron significativamente después del tratamiento en comparación con antes del tratamiento, mientras que la puntuación de la Escala de Ashworth Modificada no mostró cambios significativos. Hubo una diferencia significativa en la puntuación de la función motora del grupo CPS en comparación con la de los grupos CMS y PMS, pero no hubo una mejora significativa en la puntuación de la Escala de Ashworth Modificada. Conclusiones: La combinación de los dos métodos de tratamiento puede mejorar la función motora y las capacidades de la vida diaria de los pacientes, pero no puede mejorar el tono muscular.

2.
China Tropical Medicine ; (12): 1009-2022.
Artículo en Chino | WPRIM | ID: wpr-973835

RESUMEN

@#Abstract: Objective To investigate the distribution and drug resistance characteristics of pathogenic bacteria in patients with neutropenic acute leukemia (AL) and bloodstream infections (BSI). Methods The clinical data of 258 neutropenic acute leukemia patients with bloodstream infections, who admitted to Shengjing Hospital of China Medical University from January 2016 to December 2021, were collected and analyzed for pathogenic bacteria and drug resistance. Results A total of 268 strains of pathogenic bacteria were isolated from 258 patients, including 180 strains of gram-negative bacteria (67.16%), 61 strains of gram-positive bacteria (22.76%), and 27 strains of fungi (10.07%). Gram-negative bacteria were mainly Klebsiella pneumoniae (53/268, 19.78%), Escherichia coli (49/268, 18.28%) and Pseudomonas aeruginosa (41/268, 15.30%). Gram-positive bacteria were mainly coagulase negative Staphylococcus (31/268, 11.57%) and Staphylococcus aureus(17/268, 6.34%). The main fungi were Candida tropicalis (25/268, 9.33%). Escherichia coli (33/268, 12.31%) was the most common pathogen isolated from acute myeloid leukemia (AML), followed by Pseudomonas aeruginosa (25/268, 9.33%), coagulase-negative Staphylococcus (18/268, 6.72%) and Candida tropicalis (18/268, 6.72%). Klebsiella pneumoniae (35/268, 13.06%) was the most common pathogen isolated from acute lymphoblastic leukemia (ALL),followed by Pseudomonas aeruginosa (15/268, 5.60%) and Escherichia coli (14/268, 5.22%). The resistance of Gram-negative bacteria to piperacillin/tazobactam, cefoperazone/sulbactam, imipenem, meropenem, ertapenem, amikacin, cefoxitin, amoxicillin/clavulanic acid was low. Gram-positive bacteria were sensitive to linezolid and vancomycin. Candida was sensitive to flucytosine, amphotericin B and itraconazole. Conclusions In patients with granulosa after AL chemotherapy combined with BSI, the pathogenic bacteria isolated from AML are diverse, and the pathogenic bacteria isolated from ALL are mainly gram-negative bacteria. Pathogenic bacteria have different degrees of drug resistance to commonly used antibacterial drugs, so it is important to strengthen the monitoring of the distribution of pathogenic bacteria and the change of drug resistance and rational use of antibacterial drugs to minimize the death of patients.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA